NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report

被引：2

作者：

Rashid, Anna Misya'il Abdul ^{[1
,2
]}

Noh, Mohamad Syafeeq Faeez Md ^{[4
]}

Khan, Abdul Hanif Khan Yusof ^{[1
]}

Loh, Wei Chao ^{[1
]}

Baharin, Janudin ^{[1
]}

Ibrahim, Azliza ^{[1
]}

Mat, Liyana Najwa Inche ^{[1
]}

Sulaiman, Wan Aliaa Wan ^{[1
]}

Hoo, Fan Kee ^{[1
]}

Hanapiah, Fazah Akhtar ^{[3
]}

Basri, Hamidon ^{[1
]}

机构：

[1] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Neurol, Serdang 43400, Selangor, Malaysia

[2] Univ Putra Malaysia, Inst Penyelidikan Penuaan Malaysia MyAgeing, Serdang 43400, Selangor, Malaysia

[3] Univ Teknol MARA, Fac Med, Sungai Buloh 47000, Selangor, Malaysia

[4] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Radiol, Serdang 43400, Selangor, Malaysia

来源：

EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY | 2021年 / 57卷 / 01期

关键词：

Stroke; Chinese traditional medication; Hepatotoxicity; NeuroAid II; Elderly; TRADITIONAL CHINESE MEDICINE; MLC601 NEUROAID(R); RECOVERY; EFFICACY; WARFARIN; INFARCT; PROFILE; SAFETY; BRAIN;

D O I：

10.1186/s41983-021-00397-y

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window for reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data of drug safety and combination with other medications especially anticoagulants are heterogenous. We report a possible case of hepatotoxicity induced by NeuroAid II in combination with anticoagulants. Case presentation: We report an elderly patient who developed symptoms of cardioembolic stroke presented outside of time window for reperfusion therapy. He was started on a regiment of statins, anticoagulation, beta blockers and NeuroAid II. One month later he presented with deranged liver enzymes. Cessation of NeuroAid II resulted in rapid improvement of transaminitis within days. Conclusions: We wish to highlight the potential harmful effect of administering NeuroAid II with an anticoagulant and the importance of routine follow-up and blood monitoring in the elderly patients with stroke.

引用

页数：6

共 50 条

[21] NeuroAiD™-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models
Anjum, Anam
Yazid, Muhammad Dain
Daud, Muhammad Fauzi
Idris, Jalilah
Ng, Angela Min Hwei
Naicker, Amaramalar Selvi
Ismail, Ohnmar Htwe Rashidah
Kumar, Ramesh Kumar Athi
Lokanathan, Yogeswaran
BIOMEDICINES, 2024, 12 (08)
[22] MLC901 in subacute post-stroke recovery in the eastern European population: Preliminary results of a multicentre study
Anisovska, Anita
Janta, Mariusz
Tomasova, Anna
Gut'an, Slavomir
Garajova, Barbora
Nikolova, Iveta
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 17 - 17
[23] MLC901 IN SUBACUTE POST-STROKE RECOVERY IN THE EASTERN EUROPEAN POPULATION: PRELIMINARY RESULTS OF A MULTICENTRE STUDY
Arsovska, A.
Janta, M.
Tomasova, A.
Gut'an, S.
Garajova, B.
Nikolova, I.
INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (2_SUPPL) : 116 - 116
[24] MLC901 issued from traditional Chinese medicine favors angiogenesis and associated recovery after ischemic stroke
Gandin, C.
Widmann, C.
Lazdunski, M.
Heurteaux, C.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 111 - 111
[25] Real-world effectiveness of MLC901 in subjects after brain injuries in the eastern European population: A preliminary result of neuroaid safe treatment (nest) registry
Anisovska, Anita
Janta, Mariusz
Tomasova, Anna
Gut'an, Slavomir
Garajova, Barbora
Nikolova, Iveta
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 18 - 18
[26] NeuroAid™-II (MLC901) provides neuroprotection and enhances neuronal cell survival against kainic acid-induced excitotoxicity in vitro by activating the PI3K/AKT pathway
Anjum, Anam
Yazid, Muhammad Dain
Daud, Muhammad Fauzi
Idris, Jalilah
Ng, Angela Min Hwei
Naicker, Amaramalar Selvi
Ismail, Ohnmar Htwe
Kumar, Ramesh Kumar Athi
Lokanathan, Yogeswaran
FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 11 (01)
[27] A Randomized, placebo-controlled pilot trial to investigate the safety and efficacy of MLC901 (NEUROAID IITM) in adults following mild or moderate traumatic brain injury
Theadom, A.
Bhattacharjee, R.
Parmar, P.
Feigin, V.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 109 - 109
[28] The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial
Chen, Christopher L. H.
Sharma, Purabi Reang
Tan, Boon Yeow
Low, Casuarine
Venketasubramanian, Narayanaswamy
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 38 - 45
[29] A double-blind, placebo-controlled, randomised, multi-centre, phase III study of MLC901 (neuroaid) for the treatment of cognitive impairment after mild traumatic brain injury
Pilipenko, Pavel I.
Ivanova, Anna A.
Kotsiubinskaya, Yulia V.
Grigoryeva, Vera N.
Khrulev, Alexey Y.
Skorokhodov, Anatoly V.
Omelianenko, Min Grigorievich
Gavrik, Maxim M.
Mkrtchan, Nona N.
Majdan, Marek
Valkovic, Peter
Rabarova, Daria
Barker-Collo, Suzanne
Jones, Kelly
Feigin, Valery
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
[30] Topic: AS12 Population Health REAL-WORLD EFFECTIVENESS OF MLC901 IN SUBJECTS AFTER BRAIN INJURIES IN THE EASTERN EUROPEAN POPULATION: A PRELIMINARY RESULT OF NEUROAID SAFE TREATMENT (NEST) REGISTRY
Arsovska, A.
Janta, M.
Tomasova, A.
Gut'an, S.
Nikolova, I.
Garajova, B.
INTERNATIONAL JOURNAL OF STROKE, 2021, 16 (2_SUPPL) : 123 - 124

← 1 2 3 4 5 →